Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 6/2005

Open Access 01-12-2005 | Research article

Preclinical evaluation of transcriptional targeting strategies for carcinoma of the breast in a tissue slice model system

Authors: Mariam A Stoff-Khalili, Alexander Stoff, Angel A Rivera, Nilam S Banerjee, Maaike Everts, Scott Young, Gene P Siegal, Dirk F Richter, Minghui Wang, Peter Dall, J Michael Mathis, Zeng B Zhu, David T Curiel

Published in: Breast Cancer Research | Issue 6/2005

Login to get access

Abstract

Introduction

In view of the limited success of available treatment modalities for metastatic breast cancer, alternative and complementary strategies need to be developed. Adenoviral vector mediated strategies for breast cancer gene therapy and virotherapy are a promising novel therapeutic platform for the treatment of breast cancer. However, the promiscuous tropism of adenoviruses (Ads) is a major concern. Employing tissue specific promoters (TSPs) to restrict transgene expression or viral replication is an effective way to increase specificity towards tumor tissues and to reduce adverse effects in non-target tissues such as the liver. In this regard, candidate breast cancer TSPs include promoters of the genes for the epithelial glycoprotein 2 (EGP-2), cyclooxygenase-2 (Cox-2), α-chemokine SDF-1 receptor (stromal-cell-derived factor, CXCR4), secretory leukoprotease inhibitor (SLPI) and survivin.

Methods

We employed E1-deleted Ads that express the reporter gene luciferase under the control of the promoters of interest. We evaluated this class of vectors in various established breast cancer cell lines, primary breast cancer cells and finally in the most stringent preclinical available substrate system, constituted by precision cut tissue slices of human breast cancer and liver.

Results

Overall, the CXCR4 promoter exhibited the highest luciferase activity in breast cancer cell lines, primary breast cancer cells and breast cancer tissue slices. Importantly, the CXCR4 promoter displayed a very low activity in human primary fibroblasts and human liver tissue slices. Interestingly, gene expression profiles correlated with the promoter activities both in breast cancer cell lines and primary breast cancer cells.

Conclusion

These data suggest that the CXCR4 promoter has an ideal 'breast cancer-on/liver-off' profile, and could, therefore, be a powerful tool in Ad vector based gene therapy or virotherapy of the carcinoma of the breast.
Appendix
Available only for authorised users
Literature
1.
Lacey JV, Devesa SS, Brinton LA: Recent trends in breast cancer incidence and mortality. Environ Mol Mutagen. 2002, 39: 82-88. 10.1002/em.10062.CrossRefPubMed
2.
Gomez-Navarro J, Curiel DT, Douglas JT: Gene therapy for cancer. Eur J Cancer. 1999, 35: 867-885. 10.1016/S0959-8049(99)00061-1.CrossRefPubMed
3.
Kirn D, Martuza RL, Zwiebel J: Replication-selective virotherapy for cancer: Biological principles, risk management and future directions. Nat Med. 2001, 7: 781-787. 10.1038/89901.CrossRefPubMed
4.
Nettelbeck DM: Virotherapeutics: conditionally replicative adenoviruses for viral oncolysis. Anticancer Drugs. 2003, 14: 577-584. 10.1097/00001813-200309000-00001.CrossRefPubMed
5.
van der Eb MM, Cramer SJ, Vergouwe Y, Schagen FH, van Krieken JH, van der Eb AJ, Rinkes IH, van de Velde CJ, Hoeben RC: Severe hepatic dysfunction after adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene and ganciclovir administration. Gene Ther. 1998, 5: 451-458. 10.1038/sj.gt.3300637.CrossRefPubMed
6.
Krumdieck C: A new instrument for the rapid preparation of tissue slices. Anal Biochem. 1980, 104: 118-123. 10.1016/0003-2697(80)90284-5.CrossRefPubMed
7.
Kirby TO, Rivera A, Rein D, Wang M, Ulasov I, Breidenbach M, Kataram M, Contreras JL, Krumdieck C, Yamamoto M, et al: A novel ex vivo model system for evaluation of conditionally replicative adenoviruses therapeutic efficacy and toxicity. Clin Cancer Res. 2004, 10: 8697-8703. 10.1158/1078-0432.CCR-04-1166.CrossRefPubMed
8.
Olinga P, Groen K, Hof IH, De Kanter R, Koster HJ, Leeman WR, Rutten AA, Van Twillert K, Groothuis GM: Comparison of five incubation systems for rat liver slices using functional and viability parameters. J Pharmacol Toxicol Methods. 1997, 38: 59-69. 10.1016/S1056-8719(97)00060-9.CrossRefPubMed
9.
Smola H, Thiekotter G, Fusenig NE: Mutual induction of growth factor gene expression by epidermal-dermal cell interaction. J Cell Biol. 1993, 122: 417-429. 10.1083/jcb.122.2.417.CrossRefPubMed
10.
Stark HJ, Baur M, Breitkreutz D, Mirancea N, Fusenig NE: Organotypic keratinocyte cocultures in defined medium with regular epidermal morphogenesis and differentiation. J Invest Dermatol. 1999, 112: 681-691. 10.1046/j.1523-1747.1999.00573.x.CrossRefPubMed
11.
Satish L, Babu M, Tran KT, Hebda PA, Wells A: Keloid fibroblast responsiveness to epidermal growth factor and activation of downstream intracellular signaling pathways. Wound Repair Regen. 2004, 12: 183-192.CrossRefPubMed
12.
Zhu ZB, Makhija SK, Lu B, Wang M, Kaliberova L, Liu B, Rivera AA, Nettelbeck DM, Mahasreshti PJ, Leath CA, et al: Transcriptional targeting of adenoviral vector through the CXCR4 tumor-specific promoter. Gene Ther. 2004, 11: 645-648. 10.1038/sj.gt.3302089.CrossRefPubMed
13.
Zhu ZB, Makhija SK, Lu B, Wang M, Kaliberova L, Liu B, Rivera AA, Nettelbeck DM, Mahasreshti PJ, Leath CA, et al: Transcriptional targeting of tumors with a novel tumor-specific survivin promoter. Cancer Gene Ther. 2004, 11: 256-262. 10.1038/sj.gt.3302089.CrossRefPubMed
14.
Barker SD, Coolidge CJ, Kanerva A, Hakkarainen T, Yamamoto M, Liu B, Rivera AA, Bhoola SM, Barnes MN, Alvarez RD, et al: The secretory leukoprotease inhibitor (SLPI) promoter for ovarian cancer gene therapy. J Gene Med. 2003, 5: 300-310. 10.1002/jgm.341.CrossRefPubMed
15.
Yamamoto M, Alemany R, Adachi Y, Grizzle WE, Curiel DT: Characterization of the cyclooxygenase-2 promoter in an adenoviral vector and its application for the mitigation of toxicity in suicide gene therapy of gastrointestinal cancers. Mol Ther. 2001, 3: 385-394. 10.1006/mthe.2001.0275.CrossRefPubMed
16.
Bauerschmitz GJ, Nettelbeck DM, Kanerva A, Baker AH, Hemminki A, Reynolds PN, Curiel DT: The flt-1 promoter for transcriptional targeting of teratocarcinoma. Cancer Res. 2002, 62: 1271-1274.PubMed
17.
Rein DT, Breidenbach M, Nettelbeck DM, Kawakami Y, Siegal GP, Huh WK, Wang M, Hemminki A, Bauerschmitz GJ, Yamamoto M, et al: Evaluation of tissue-specific promoters in carcinomas of the cervix uteri. J Gene Med. 2004, 6: 1281-1289. 10.1002/jgm.606.CrossRefPubMed
18.
Huard J, Lochmuller H, Acsadi G, Jani A, Massie B, Karpati G: The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants. Gene Ther. 1995, 2: 107-115.PubMed
19.
Nettelbeck DM, Jerome V, Muller R: Gene therapy designer promoters for tumour targeting. Trends Genet. 2000, 16: 174-181. 10.1016/S0168-9525(99)01950-2.CrossRefPubMed
20.
Adachi Y, Matsubara S, Muramatsu T, Curiel DT, Reynolds PN: Midkine promoter-based adenoviral suicide gene therapy to midkine-positive pediatric tumor. J Pediatr Surg. 2002, 37: 588-592. 10.1053/jpsu.2002.31615.CrossRefPubMed
21.
Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, Lipsky PE: Cyclooxygenase in biology and disease. Faseb J. 1998, 12: 1063-1073.PubMed
22.
Kanerva A, Bauerschmitz GJ, Yamamoto M, Lam JT, Alvarez RD, Siegal GP, Curiel DT, Hemminki A: A cyclooxygenase-2 promoter-based conditionally replicating adenovirus with enhanced infectivity for treatment of ovarian adenocarcinoma. Gene Ther. 2004, 11: 552-559. 10.1038/sj.gt.3302181.CrossRefPubMed
23.
Yamamoto M, Davydova J, Wang M, Siegal GP, Krasnykh V, Vickers SM, Curiel DT: Infectivity enhanced, cyclooxygenase-2 promoter-based conditionally replicative adenovirus for pancreatic cancer. Gastroenterology. 2003, 125: 1203-1218. 10.1016/S0016-5085(03)01196-X.CrossRefPubMed
24.
Nettelbeck DM, Rivera AA, Davydova J, Dieckmann D, Yamamoto M, Curiel DT: Cyclooxygenase-2 promoter for tumour-specific targeting of adenoviral vectors to melanoma. Melanoma Res. 2003, 13: 287-292. 10.1097/00008390-200306000-00010.CrossRefPubMed
25.
Wesseling JG, Yamamoto M, Adachi Y, Bosma PJ, van Wijland M, Blackwell JL, Li H, Reynolds PN, Dmitriev I, Vickers SM, et al: Midkine and cyclooxygenase-2 promoters are promising for adenoviral vector gene delivery of pancreatic carcinoma. Cancer Gene Ther. 2001, 8: 990-996. 10.1038/sj.cgt.7700403.CrossRefPubMed
26.
Marks F, Furstenberger G: Cancer chemoprevention through interruption of multistage carcinogenesis. The lessons learnt by comparing mouse skin carcinogenesis and human large bowel cancer. Eur J Cancer. 2000, 36: 314-329. 10.1016/S0959-8049(99)00318-4.CrossRefPubMed
27.
Hwang D, Scollard D, Byrne J, Levine E: Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst. 1998, 90: 455-460. 10.1093/jnci/90.6.455.CrossRefPubMed
28.
Soslow RA, Dannenberg AJ, Rush D, Woerner BM, Khan KN, Masferrer J, Koki AT: COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer. 2000, 89: 2637-2645. 10.1002/1097-0142(20001215)89:12<2637::AID-CNCR17>3.0.CO;2-B.CrossRefPubMed
29.
Garver RI, Goldsmith KT, Rodu B, Hu PC, Sorscher EJ, Curiel DT: Strategy for achieving selective killing of carcinomas. Gene Ther. 1994, 1: 46-50.PubMed
30.
Wegner SA, Ehrenberg PK, Chang G, Dayhoff DE, Sleeker AL, Michael NL: Genomic organization and functional characterization of the chemokine receptor CXCR4, a major entry co-receptor for human immunodeficiency virus type 1. J Biol Chem. 1998, 273: 4754-4760. 10.1074/jbc.273.8.4754.CrossRefPubMed
31.
Sarela AI, Verbeke CS, Ramsdale J, Davies CL, Markham AF, Guillou PJ: Expression of survivin, a novel inhibitor of apoptosis and cell cycle regulatory protein, in pancreatic adenocarcinoma. Br J Cancer. 2002, 86: 886-892. 10.1038/sj.bjc.6600133.CrossRefPubMedPubMedCentral
32.
Ikeguchi M, Yamaguchi K, Kaibara N: Survivin gene expression positively correlates with proliferative activity of cancer cells in esophageal cancer. Tumour Biol. 2003, 24: 40-45. 10.1159/000070659.CrossRefPubMed
33.
Das A, Tan WL, Smith DR: Expression of the inhibitor of apoptosis protein survivin in benign meningiomas. Cancer Lett. 2003, 193: 217-223. 10.1016/S0304-3835(02)00741-3.CrossRefPubMed
34.
Zaffaroni N, Pennati M, Colella G, Perego P, Supino R, Gatti L, Pilotti S, Zunino F, Daidone MG: Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cell Mol Life Sci. 2002, 59: 1406-1412. 10.1007/s00018-002-8518-3.CrossRefPubMed
35.
Chiodino C, Cesinaro AM, Ottani D, Fantini F, Giannetti A, Trentini GP, Pincelli C: Communication: expression of the novel inhibitor of apoptosis survivin in normal and neoplastic skin. J Invest Dermatol. 1999, 113: 415-418. 10.1046/j.1523-1747.1999.00711.x.CrossRefPubMed
36.
McLaughlin PM, Harmsen MC, Dokter WH, Kroesen BJ, van der Molen H, Brinker MG, Hollema H, Ruiters MH, Buys CH, de Leij LF: The epithelial glycoprotein 2 (EGP-2) promoter-driven epithelial-specific expression of EGP-2 in transgenic mice: a new model to study carcinoma-directed immunotherapy. Cancer Res. 2001, 61: 4105-4111.PubMed
37.
Basak S, Speicher D, Eck S, Wunner W, Maul G, Simmons MS, Herlyn D: Colorectal carcinoma invasion inhibition by CO17-1A/GA733 antigen and its murine homologue. J Natl Cancer Inst. 1998, 90: 691-697. 10.1093/jnci/90.9.691.CrossRefPubMed
38.
Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, et al: Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001, 410: 50-56. 10.1038/35065016.CrossRefPubMed
39.
Payne AS, Cornelius LA: The role of chemokines in melanoma tumor growth and metastasis. J Invest Dermatol. 2002, 118: 915-922. 10.1046/j.1523-1747.2002.01725.x.CrossRefPubMed
40.
Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK: Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res. 2002, 62: 1832-1837.PubMed
41.
Casado E, Gomez-Navarro J, Yamamoto M, Adachi Y, Coolidge CJ, Arafat WO, Barker SD, Wang MH, Mahasreshti PJ, Hemminki A, et al: Strategies to accomplish targeted expression of transgenes in ovarian cancer for molecular therapeutic applications. Clin Cancer Res. 2001, 7: 2496-2504.PubMed
42.
Wang Y, Thorne S, Hannock J, Francis J, Au T, Reid T, Lemoine N, Kirn D, Hallden G: A novel assay to assess primary human cancer infectibility by replication-selective oncolytic adenoviruses. Clin Cancer Res. 2005, 11: 351-360.PubMed
43.
Alemany R, Suzuki K, Curiel DT: Blood clearance rates of adenovirus type 5 in mice. J Gen Virol. 2000, 81: 2605-2609.CrossRefPubMed
44.
Bernt KM, Ni S, Gaggar A, Li ZY, Shayakhmetov DM, Lieber A: The effect of sequestration by nontarget tissues on anti-tumor efficacy of systemically applied, conditionally replicating adenovirus vectors. Mol Ther. 2003, 8: 746-755. 10.1016/j.ymthe.2003.07.006.CrossRefPubMed
45.
Lieber A, He CY, Meuse L, Schowalter D, Kirillova I, Winther B, Kay MA: The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors. J Virol. 1997, 71: 8798-8807.PubMedPubMedCentral
46.
Jessen BA, Mullins JS, De Peyster A, Stevens GJ: Assessment of hepatocytes and liver slices as in vitro test systems to predict in vivo gene expression. Toxicol Sci. 2003, 75: 208-222. 10.1093/toxsci/kfg172.CrossRefPubMed
Metadata
Title
Preclinical evaluation of transcriptional targeting strategies for carcinoma of the breast in a tissue slice model system
Authors
Mariam A Stoff-Khalili
Alexander Stoff
Angel A Rivera
Nilam S Banerjee
Maaike Everts
Scott Young
Gene P Siegal
Dirk F Richter
Minghui Wang
Peter Dall
J Michael Mathis
Zeng B Zhu
David T Curiel
Publication date
01-12-2005
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 6/2005
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr1353

Other articles of this Issue 6/2005

Breast Cancer Research 6/2005 Go to the issue

Research article

Antisense oligonucleotides targeting the progesterone receptor inhibit hormone-independent breast cancer growth in mice

Research article

XRCC1 and XPDgenetic polymorphisms, smoking and breast cancer risk in a Finnish case-control study

Research article

Prognostic relevance of disseminated tumor cells in the bone marrow and biological factors of 265 primary breast carcinomas

Research article

Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis

Research article

Allelic imbalances of chromosomes 8p and 18q and their roles in distant relapse of early stage, node-negative breast cancer

Research article

Genetic polymorphisms in human SULT1A1 and UGT1A1 genes associate with breast tumor characteristics: a case-series study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits